...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of the Endocrine Society. >MON-LB102 Metformin-Induced Weight Loss in Patients With or Without Type 2 Diabetes/Prediabetes
【24h】

MON-LB102 Metformin-Induced Weight Loss in Patients With or Without Type 2 Diabetes/Prediabetes

机译：mon-lb102二甲双胍诱导的患者体重减轻或不含2型糖尿病/前奶油

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background : Metformin is the first-line pharmacologic treatment for type 2 diabetes (T2DM). Its use has been associated with significant weight loss in patients with obesity with or without T2DM. However, it is unknown whether weight loss outcomes differ with metformin monotherapy in patients with excess weight and euglycemia compared to patients with T2DM/prediabetes (PreDM). Methods : This is a retrospective study of new patients with overweight/obesity seen at an academic weight management center between 4/1/14-4/1/16. Patients who received metformin as a sole pharmacotherapy were identified, and data pertaining to demographics, medications, comorbidities, and weight changes during 1-year follow-up were obtained from their electronic medical records. Mean and categorical weight losses were compared between patients with and without T2DM/PreDM. We also assessed the rate of metformin discontinuation due to side effects, lack of efficacy or other reasons in the entire cohort. Results: Of 1056 patients who were prescribed metformin for weight loss over the 2-year study period and had at least 2 office visits, 99 (9.38%) discontinued the medication due to the following reasons: side effects 59 (60%), lack of efficacy 15(15%) or other reasons 25(25%). A total of 254 patients received metformin as a sole pharmacotherapy for weight loss and had 6 and/or 12-month follow-up visits. In this cohort, the mean age was 53 ± 14 years, 66% were women. The mean BMI was 35 ± 7 kg/m2. The average percent weight loss at 6 and 12 months were similar in patients with euglycemia compared to patients with T2DM/PreDM (6.12% ± 5.68 vs 6.36% ± 6.52 p=0.73 at 6 months; 7.13% ± 6.42 vs 7.23% ± 7.74 p=0.93 at 12 months). The proportion of patients who experienced ≥5% weight loss was similar in both groups at 6-month (54.04 vs 54.55%, p=0.94) and 12-month follow-up visits (63.95 vs 55.42%, p=0.26). The proportion of patients who experienced ≥10% weight loss was also similar in both groups at 6-month (25.81 vs 27.72%, p=0.81) and 12-month follow-up visits (33.72 vs 30.12%, p=0.62). Discussion : Among patients with obesity, metformin as a sole pharmacotherapy for weight loss achieved significant and comparable weight reduction in patients with or without T2DM/PreDM. Further studies are needed to evaluate the long-term weight loss in patients with euglycemia.
机译：背景：二甲双胍是2型糖尿病（T2DM）的一线药物治疗。它的使用与肥胖患者有或没有T2DM的患者有关。然而，与T2DM / Predibites（PredM）患者相比，重量损失结果是否与体重减轻和晚期患者的重量损失结果不同。方法：这是在4/1 / 14-4 / 1/16之间的学术重量管理中心看到的新患者的回顾性研究。鉴定了接受二甲双胍作为唯一药物疗法的患者，并从他们的电子病历中获得了1年后的人口统计学，药物，组合和体重变化的数据。在没有T2DM / predM的患者之间比较平均值和分类的体重减轻。我们还通过副作用评估了二甲双胍停止率，整个队列中缺乏疗效或其他原因。结果：1056名患者在2年度研究期间进行体重减轻的患者，至少有2个办公室访问，99名（9.38％）由于以下原因出现了药物：副作用59（60％），缺乏疗效15（15％）或其他原因25（25％）。共有254名患者接受二甲双胍作为体重减轻的唯一药物治疗，并有6个和/或12个月的后续访问。在这种队列中，平均年龄为53±14岁，66％是女性。平均BMI为35±7千克/平方米。与T2DM / PredM的患者相比，患有T2DM / PredM的患者的患者的平均体重减轻在6和12个月内相似（6.12％±5.68 Vs 6.36％±6.52 p = 0.73; 7.13％±6.42与7.23％±7.74 p 12个月= 0.93）。在6个月的两组中，经历≥5％减肥的患者的比例在6个月（54.04 vs 54.55％，p = 0.94）和12个月的后续访问（63.95 Vs 55.42％，p = 0.26）。在6个月的两个群体中经历≥10％减肥的患者的比例也相似（25.81 vs 27.72％，p = 0.81）和12个月的随访访问（33.72 vs 30.12％，p = 0.62）。讨论：肥胖症患者中，二甲双胍作为体重减轻的唯一药物疗法取得了或没有T2DM / PredM的患者的显着和相当的重量。需要进一步的研究来评估患有Euglycemia患者的长期减肥。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号